What Happens If You Take Too Much Phenobarbital?

Taking too much phenobarbital suppresses the central nervous system in a cascading way: mild drowsiness progresses to deep sedation, then to respiratory failure, cardiovascular collapse, and coma. In severe cases, the overdose can be fatal. What makes phenobarbital particularly dangerous compared to many other drugs is its extraordinarily long half-life, which means toxic levels can persist in the body for days, and the window between a therapeutic dose and a life-threatening one is relatively narrow.

Early Signs of an Overdose

The first symptoms of too much phenobarbital center on the brain. Because the drug works by enhancing a calming neurotransmitter, an excess dose amplifies that effect beyond what is useful. Early signs include pronounced drowsiness, confusion, slurred speech, poor coordination, and involuntary eye movements. A person may seem heavily intoxicated even though they have not been drinking. These symptoms can appear deceptively mild at first, especially in someone who already takes the drug regularly and has built up some tolerance.

As blood levels climb, sedation deepens. The person becomes increasingly difficult to rouse. Reflexes weaken, and muscle tone drops. At this stage the overdose is already moving toward dangerous territory, because the same brain suppression that causes sleepiness also starts to affect the regions controlling breathing and heart function.

What Happens in a Severe Overdose

In a serious phenobarbital overdose, the two greatest threats are respiratory depression and cardiovascular collapse. Breathing slows, becomes shallow, and can stop altogether without intervention. Blood pressure drops, sometimes severely, and body temperature can fall below normal. Cardiac arrest is possible in extreme cases.

The reported fatal dose in medical literature is roughly 10 grams, corresponding to a blood level around 80 mg/L, though individual tolerance varies enormously.

One published case describes a patient who ingested roughly twice that fatal dose and remained hemodynamically stable, likely because years of daily use had built significant tolerance.

That kind of variability is part of what makes phenobarbital overdose so unpredictable: a dose that a chronic user survives could kill someone taking the drug for the first time.

In children and infants, the picture looks somewhat different. A systematic review of pediatric phenobarbital poisoning found that, beyond the expected lethargy and sedation, children also developed fever, skin rash, liver inflammation, hair loss, and in severe cases, heart muscle failure, abnormal hormone secretion, and coma.

Why the Drug Stays in Your System So Long

One of the most clinically important features of phenobarbital overdose is how slowly the body clears it. After swallowing a dose, phenobarbital is absorbed through the gut and reaches peak blood levels in about two hours. But the drug’s half-life in adults is roughly 75 to 120 hours, meaning it can take three to five days for blood levels to drop by half. About 45 to 60 percent of the drug binds to proteins in the blood, and only around a quarter is excreted unchanged in the urine at normal pH.

This slow clearance means that even after someone stops absorbing the drug, toxic levels hang around for days. A patient admitted to the hospital with a phenobarbital overdose is not in and out overnight. Extended intensive care, often including days on a ventilator, is common. That long exposure window also increases the risk of secondary complications like pneumonia from prolonged immobility or pressure injuries from sustained unconsciousness.

Skin Blisters That Signal Barbiturate Poisoning

One lesser-known consequence of phenobarbital overdose is the development of blisters on the skin, sometimes called “coma blisters” or “barbiturate blisters.” In a large case series, these lesions appeared in about 6.5 percent of 290 patients with acute barbiturate poisoning, sometimes showing up within four hours of ingestion. The structural damage is concentrated in sweat glands and ducts, which can show partial or total tissue death even when the outer skin looks relatively intact.

For years, the medical assumption was that these blisters only formed after coma-inducing doses. A case report challenged that idea, documenting a patient who was neither comatose nor immobilized but still developed widespread blisters after taking oral phenobarbital at levels below the toxic threshold. The blisters resolved on their own within two weeks, requiring only care similar to treating a superficial burn.

⁴

The takeaway for anyone on phenobarbital is that unexplained blistering skin lesions after a dose increase or accidental extra dose should prompt medical attention, even if you feel otherwise alert.

When an Overdose Mimics Brain Death

Perhaps the most alarming clinical scenario with phenobarbital overdose is how closely it can mimic brain death. Severe intoxication can suppress virtually all detectable brain activity, eliminate reflexes, and produce a patient who appears, by many clinical criteria, to have irreversible brain damage. This is especially true in people who do not take phenobarbital regularly and have no built-up tolerance.

⁵

This mimicry has real stakes. Clinicians assessing an unresponsive patient must rule out drug intoxication before making any determination about brain death, because unlike actual brain death, a phenobarbital-induced coma is reversible once the drug is cleared. Standard brain-death testing protocols include drug screening for exactly this reason. Cases have been documented where patients who appeared to have no brain function made full recoveries once the phenobarbital was eliminated. The lengthy half-life means this false appearance can persist for days, testing the patience and judgment of medical teams and families alike.

How Phenobarbital Overdose Is Treated

Treatment for phenobarbital overdose starts with keeping the patient alive: securing the airway, supporting breathing with mechanical ventilation if necessary, and using fluids or medications to maintain blood pressure. Beyond that supportive care, the main strategies aim to speed the removal of phenobarbital from the body.

Activated Charcoal

The first-line approach for enhancing elimination is giving multiple doses of activated charcoal through a tube into the stomach. Charcoal binds to phenobarbital in the gut, and because the drug recirculates between the blood and the intestines, repeated doses can pull it out of the bloodstream over time. In one study, the drug’s half-life dropped from 148 hours during a control phase to just 19 hours during multiple-dose charcoal treatment.

⁶

In an infant case, the approach cut the half-life to about 11 hours, well below the expected range, and the child recovered quickly.

⁷

Early reports called this the method of choice for speeding phenobarbital elimination, and it remains a mainstay of treatment.

⁸

Urinary Alkalinization

Because a portion of phenobarbital is excreted unchanged in the urine, making the urine more alkaline (usually with intravenous sodium bicarbonate) can increase how much of the drug the kidneys flush out. A pharmacokinetic analysis of a patient treated with alkalinization alone found that it did increase phenobarbital in the urine, but the researchers could not demonstrate a clear relationship between that increased excretion and meaningfully faster elimination from the blood. They concluded the clinical benefit of alkalinization on its own was uncertain.

⁵

Forced alkaline diuresis, a more aggressive older technique, is no longer recommended.

⁹

Dialysis and Blood Purification

For the most serious cases, where the patient is in a coma, not responding to charcoal, or showing signs of cardiovascular instability, machines can be used to filter the drug directly from the blood. Hemodialysis using high-efficiency equipment has been shown to clear phenobarbital effectively, with one case reporting clearance rates that exceeded most published results for hemoperfusion (a related technique using a charcoal filter cartridge). That case also demonstrated rapid improvement in the patient’s condition after dialysis.

¹⁰

Some clinicians have argued that waiting for multiple-dose charcoal to take effect in a deeply comatose patient adds unnecessary risk, since the charcoal approach can take days to bring levels down adequately. In such cases, aggressive blood purification may shorten the duration of coma and reduce the chances of complications from prolonged unconsciousness.

¹¹

Hemodialysis has practical advantages over hemoperfusion as well: it is more widely available in hospitals, the staff running it are more familiar with the equipment, and it does not carry the same risk of destroying blood platelets.

¹⁰

Alcohol and Other Substances That Amplify the Danger

Phenobarbital is dangerous enough on its own in overdose, but the risk escalates sharply when other substances are involved. Alcohol is the most common culprit. Both alcohol and phenobarbital depress the central nervous system, and when combined, their sedative effects are at least additive and potentially synergistic.

¹²

Experimental work has shown that combining ethanol with phenobarbital produces additive effects on motor impairment and can potentiate the loss of protective reflexes.

¹³

Other central nervous system depressants compound the problem in the same way. Benzodiazepines, opioids, muscle relaxants, and sedating antihistamines all push breathing and blood pressure in the same downward direction that phenobarbital does. A dose of phenobarbital that would cause manageable drowsiness on its own can become lethal in combination with even moderate amounts of these other substances. This is one reason accidental overdoses happen: someone on a stable phenobarbital prescription takes a sleeping pill or has a few drinks, and the combined sedation overwhelms the body’s ability to maintain breathing.

Why Older Adults and Children Face Higher Risk

The body handles phenobarbital differently at the extremes of age, and both children and older adults are disproportionately vulnerable to overdose effects. In older adults, age-related changes in liver function, kidney function, and the amount of protein available to bind the drug all shift the pharmacokinetics in unfavorable directions. Less protein binding means more free drug circulating in the blood. Slower liver metabolism means the already-long half-life gets even longer. Reduced kidney function further delays clearance.

¹⁴

These physiological changes make older adults more susceptible to side effects at standard doses, let alone in overdose situations.

¹⁵

In newborns and young children, the picture is complicated by immature metabolic pathways and a higher ratio of body water to fat, which changes how the drug distributes through the body. Infants who are poisoned may show signs that parents would not immediately connect to a drug problem: poor feeding, unusual sleepiness, and fever. The transition from “sleepy baby” to “critically ill baby” can happen fast, which is why any suspicion of accidental ingestion warrants emergency evaluation. The pediatric literature also documents complications not commonly seen in adults, including abnormal hormone secretion and liver inflammation.

The Tolerance Problem

Tolerance is the wild card in phenobarbital toxicology. Someone who has taken the drug daily for months or years develops physiological adaptation to its sedative effects. Their brain essentially recalibrates around the constant presence of the drug, so a blood level that would put a first-time user in a coma might leave a chronic user merely drowsy. The case mentioned earlier, where a patient survived roughly twice the reported fatal dose, is a striking example of how far tolerance can shift the lethal threshold.

This creates a paradox that trips up patients and sometimes clinicians. A long-term user might assume they can handle higher amounts and take extra doses during a breakthrough seizure, not realizing they are approaching a threshold where respiratory depression outpaces their tolerance. Conversely, if a tolerant person stops taking the drug and then resumes at their previous dose weeks later, the tolerance has faded and what was once a normal dose is now an overdose. Interestingly, one study found no straightforward relationship between measured blood levels of antiepileptic drugs and the side effects patients experienced, underscoring how much individual biology muddies the picture.

¹⁶

Body Temperature and Metabolic Disruptions

Textbooks list hypothermia, a drop in core body temperature, as a classic feature of barbiturate overdose. The drug suppresses the brain’s temperature-regulating center, and combined with loss of consciousness and immobility, patients can lose heat rapidly. Yet the clinical reality is not always so clean-cut. A study at a major poisoning referral center in Tehran surveyed temperature abnormalities in poisoned patients and reported that hypothermia was surprisingly absent from their data, even though the study included phenobarbital poisoning cases.

¹⁷

This does not mean hypothermia never happens in phenobarbital overdose; it does, and clinical guidelines still flag it as a risk. But it may be less universal than older literature suggested, possibly because modern emergency departments warm patients more effectively or because the ambient environment and co-ingested substances influence body temperature in complex ways. In pediatric cases, fever has actually been reported as a sign of phenobarbital toxicity, which runs counter to the expected hypothermia and can confuse the clinical picture.

1
Journal of Clinical Nephrology and Renal Care. Effective Role of CVVH in Fatal Phenobarbital Overdose Clearance: A Case Report
2
PubMed. Acute Phenobarbital Poisoning for the Management of Seizures in Newborns and Children; A Systematic Literature Review
3
Anais Brasileiros de Dermatologia. Coma blisters after poisoning caused by central nervous system depressants: case report including histopathological findings
4
PubMed Central. Phenobarbital-induced bullous lesions in a non-comatose patient
5
PubMed Central. Pharmacokinetic analysis of a phenobarbital overdose treated with urinary alkalinization alone
6
PubMed. Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination
7
PubMed. Treatment of phenobarbital poisoning with multiple dose activated charcoal in an infant
8
PubMed. Treatment of phenobarbital overdose with activated charcoal
9
PubMed Central. Antiepileptic Overdose
10
PubMed. Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose
11
PubMed Central. Efficacy of direct hemoperfusion for the removal of phenobarbital through blood concentration analysis
12
PubMed Central. Alcohol and medication interactions
13
Toxicology and Applied Pharmacology. The effects of ethanol alone and in combination with phenobarbital, chlorpromazine, or chlordiazepoxide
14
PubMed. Antiepileptic drug therapy in the elderly: a clinical pharmacological review
15
PubMed. Selection of antiepileptic drugs in older people
16
PubMed Central. Correlation between Serum Level of Antiepileptic Drugs and their Side Effects
17
PubMed Central. Survey on Hypothermia and Hyperthermia in Poisoned Patients in a Unique Referral Hospital, Tehran, Iran